The testing seeks to use cell cultures that require a microgravity environment to grow.
"It’s a very effective therapy [but] the concern for our drug is safety," Jaminet stated. "Because we target the blood vessels of the tumor, there’s a risk of toxicity against the normal blood vessels of the body."
Previous International Space Station experiments have demonstrated that the endothelial cells that line human blood vessels — which cannot be grown in test tubes and Petri dishes on Earth — can be grown in the microgravity of low-Earth orbit, Jaminet explained.
Astronauts will test NGX drug on the International Space Station as one of hundreds of scientific experiments included in the next resupply payload, according to NASA.